Registered title, quoted from ClinicalTrials.gov
A Study Comparing BL-B01D1 in Combination With PD-1/VEGF Bispecific Antibody Versus Chemotherapy in Combination With PD-1/VEGF Bispecific Antibody in First-line Patients With Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer(PANKU-Lung05)
An open trial on lung cancer, registered on ClinicalTrials.gov. The lead sponsor is not a hospital on this site; 2 hospitals on this site are listed as study sites.
Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.
The study team’s contact details are on the registry record. This site does not pass on enquiries.
Hospitals in mainland China listed for this trial 2
Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.
- Study siteSun Yat-sen University Cancer Center中山大学肿瘤防治中心GuangzhouHospital page
- Study siteUnion Hospital华中科技大学同济医学院附属协和医院WuhanHospital page
The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov
Source: ClinicalTrials.gov record NCT07739199, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched
Checklist for this trial 5
Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.
Show the checklist (5 points)Hide the checklist
18 years to Not stated; sex: all
Registered eligibility fields
Toxicities from prior anti-tumor therapy must have recovered to ≤ Grade 1 as defined by NCI-CTCAE v6.0;
Inclusion criterion 8
Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1;
Inclusion criterion 7
Must have at least one measurable lesion as defined by RECIST v1.1;
Inclusion criterion 6
Prior histological or cytological evidence of small cell lung cancer, neuroendocrine carcinoma, or carcinosarcoma components;
Exclusion criterion 1
Diagnosis of active malignancy within 3 years before study randomization;
Exclusion criterion 12
Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: diagnosis and how it was confirmed; stage or severity, as the trial defines it; blood tests: counts, liver and kidney function; pregnancy, breastfeeding and contraception.
Questions to ask the study team
Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07739199, read on 10 Nov 2026.
Registered criteria
Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.
Inclusion Criteria:
- Voluntarily sign the informed consent form and comply with the protocol requirements;
- Age ≥18 years;
- Expected survival time ≥3 months;
- Patients with locally advanced or metastatic squamous non-small cell lung cancer;
- Agree to provide tumor tissue samples obtained at or after the diagnosis of locally advanced or metastatic disease;
- Must have at least one measurable lesion as defined by RECIST v1.1;
- Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1;
- Toxicities from prior anti-tumor therapy must have recovered to ≤ Grade 1 as defined by NCI-CTCAE v6.0;
- No severe cardiac dysfunction, with left ventricular ejection fraction ≥50%;
- Organ function levels must meet the specified requirements;
- Urinary protein ≤1+ or <1000 mg/24h;
- For premenopausal women of childbearing potential, a pregnancy test must be performed within 7 days before starting treatment, with serum pregnancy test excluding pregnancy, and patients must be non-lactating; all enrolled patients (regardless of male or female) must take adequate barrier contraceptive measures throughout the entire treatment period and for 7 months after the end of treatment.
Exclusion Criteria:
- Prior histological or cytological evidence of small cell lung cancer, neuroendocrine carcinoma, or carcinosarcoma components;
- Indications of the presence of EGFR-sensitive mutations, among others;
- Patients who have received prior systemic therapy;
- Prior treatment with agents targeting the mechanism of tumor immune action;
- Prior treatment with ADC drugs that use topoisomerase I inhibitors as the toxin, among others;
- Receipt of radical radiotherapy, major surgery, or large-field radiotherapy within 4 weeks before study randomization;
- History of severe heart disease or cerebrovascular disease;
- Receipt of long-term systemic corticosteroid therapy (e.g., prednisone >10 mg/day) before the first dose;
- Active autoimmune diseases and inflammatory diseases requiring systemic treatment within 2 years;
- Unstable thrombotic events requiring therapeutic intervention within 6 months before screening;
- Prolonged QTc interval, complete left bundle branch block, among others;
- Diagnosis of active malignancy within 3 years before study randomization;
- Hypertension inadequately controlled by two antihypertensive medications;
- Patients with poorly controlled blood glucose levels;
- History of ILD requiring steroid therapy, current ILD, or grade ≥2 radiation pneumonitis, among others;
- Pulmonary diseases leading to clinically severe impairment of respiratory function;
- Patients with active central nervous system metastases;
- Severe infection occurring within 4 weeks before study randomization;
- Presence of large serous cavity effusions or symptomatic serous cavity effusions, among others;
- Imaging findings indicating tumor invasion or encasement of the abdomen, chest, etc.;
- Severe non-healing wounds, ulcers, or fractures within 4 weeks before signing informed consent;
- Trial participants with clinically significant bleeding or a significant bleeding tendency within 4 weeks prior to signing informed consent;
- Patients with inflammatory bowel disease, history of extensive bowel resection, history of immune enteritis, intestinal obstruction, or chronic diarrhea, among others;
- History of allergy to recombinant humanized antibodies or hypersensitivity to any excipient of BL-B01D1;
- History of autologous or allogeneic stem cell transplantation;
- Positive for human immunodeficiency virus antibody, active hepatitis B virus infection, or hepatitis C virus infection;
- History of severe neurological or psychiatric disorders;
- Receipt of other unapproved clinical study drugs or treatments within 4 weeks before study randomization;
- Trial participants planning to receive or having received live vaccines within 28 days before study randomization;
- Other conditions deemed by the investigator as unsuitable for participation in this clinical trial due to complications or other circumstances.
Quoted from ClinicalTrials.gov, NCT07739199, participation criteria. Read on 10 Nov 2026.
Where this information comes from
The registry record
ClinicalTrials.gov (US National Library of Medicine), record NCT07739199, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.
Diseases and hospitals
The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions
What is left out
Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.